Form 4: Bristol-Myers Squibb Executive Karin Shanahan Reports Changes in Beneficial Ownership

EVP Karin Shanahan reports transactions involving Bristol-Myers Squibb common stock and derivative securities, including vesting of market share units and performance shares.

Summary

• Karin Shanahan, EVP at Bristol-Myers Squibb, filed a Form 4 detailing changes in her beneficial ownership of the company's stock.
• The transactions occurred on March 10, 2025, and involve the vesting of market share units and performance shares.
• Shanahan acquired and disposed of common stock due to the vesting of these awards and the withholding of shares for tax payments.
• She also acquired additional market share units and performance shares that will vest in the future.
• Following these transactions, Shanahan directly owns 12,183 shares of common stock and indirectly owns 919.462 shares through the BMS Savings and Investment Program.
• She also holds derivative securities, including market share units and performance shares, which will convert into common stock in the future.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices and suggests that performance goals are being met, leading to a moderately positive sentiment.

Positives

• The vesting of market share units and performance shares indicates that certain performance goals were likely met, which is a positive sign for the company.
• The acquisition of new market share units and performance shares incentivizes the executive to continue driving company performance.

Negatives

• The disposal of shares to cover tax obligations reduces the executive's direct ownership stake, although this is a common practice.

Risks

• Fluctuations in the company's stock price could impact the value of the market share units and performance shares.
• Failure to meet future performance goals could result in a lower payout factor for the market share units.

Future Outlook

The document indicates that Shanahan holds additional market share units and performance shares that will vest in the future, subject to continued employment and the achievement of performance goals.

Industry Context

Form 4 filings are a routine part of executive compensation and provide transparency into the alignment of management's interests with those of shareholders. The vesting of performance-based equity awards suggests that the company is meeting its strategic objectives.

Comparison to Industry Standards

• Executive compensation packages at large pharmaceutical companies like Bristol-Myers Squibb typically include a mix of salary, bonus, stock options, and restricted stock units.
• Companies like Pfizer, Johnson & Johnson, and Merck also utilize market share units and performance shares to incentivize executives to achieve long-term strategic goals.
• The payout factors for market share units, ranging from 80% to 225%, are within the typical range for performance-based equity awards in the pharmaceutical industry.
• The vesting schedules for market share units and performance shares, typically three years, are also consistent with industry standards.

Stakeholder Impact

• Shareholders may view the vesting of performance-based equity awards as a positive sign, indicating that management is aligned with their interests and that the company is achieving its strategic objectives.
• Employees may be motivated by the potential to earn similar equity awards in the future.
• The transactions reported in the Form 4 have a minimal impact on customers, suppliers, and creditors.

Next Steps

• The market share units granted on 03/10/2025 will cliff vest on the third anniversary of the grant date, subject to certification of performance results by the Board.
• The performance shares granted on 03/10/2025 will convert into one share of common stock upon distribution in the first quarter of 2028, subject to certification of performance results by the Board.

Key Dates